Bo Kruse - 30 May 2024 Form 4 Insider Report for Y-mAbs Therapeutics, Inc. (YMAB)

Role
EVP, CFO, SECRY & TREAS.
Signature
/s/ John LaRocca, Attorney-in-Fact
Issuer symbol
YMAB
Transactions as of
30 May 2024
Net transactions value
-$603,055
Form type
4
Filing time
31 May 2024, 21:36:00 UTC
Previous filing
22 Jan 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction YMAB Common Stock Options Exercise $57,258 +28,629 +14% $2.00 239,506 30 May 2024 Direct
transaction YMAB Common Stock Sale $344,407 -28,629 -12% $12.03 210,877 30 May 2024 Direct F1
transaction YMAB Common Stock Options Exercise $62,742 +31,371 +15% $2.00 242,248 31 May 2024 Direct
transaction YMAB Common Stock Sale $378,648 -31,371 -13% $12.07 210,877 31 May 2024 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction YMAB Employee Stock Option (right to buy) Options Exercise $0 -28,629 -9.5% $0.000000 271,371 30 May 2024 Common Stock 28,629 $2.00 Direct F3
transaction YMAB Employee Stock Option (right to buy) Options Exercise $0 -31,371 -12% $0.000000 240,000 31 May 2024 Common Stock 31,371 $2.00 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This transaction was executed in multiple trades at prices ranging from $11.85 to $12.22, inclusive. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected.
F2 This transaction was executed in multiple trades at prices ranging from $11.87 to $12.42, inclusive. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected.
F3 All of these stock options are currently vested.